【摘要】 目的 探索广泛期小细胞肺癌(ES-SCLC)一线免疫联合化疗后进行巩固胸部放疗(TRT)的疗效和安全性。方法 纳入2024年2月至2025年4月期间在滨州医学院附属医院接受一线免疫联合化疗的共35例ES-SCLC患者,其中只接受免疫联合化疗的患者被归类为队列A(n=19),后续胸部巩固放疗的患者被归类为队列B(n=16)。主要研究终点为总生存率(OS)及无进展生存期(PFS),次要研究终点为治疗安全性。结果 在35例ES-SCLC患者中,队列A和队列B分别为19例和16例,中位PFS分别为5.3个月和9.1个月,而生存差异有统计学意义(P<0.05)。中位OS分别为6.3个月和10.3个月,生存差异有统计学意义(P<0.05),两组间治疗不良反应的发生无显著性差异(P>0.05)。结论 免疫联合化疗后进行胸部巩固放疗,PFS和OS均有所改善,且整体安全性仍然可控。更多还原

【Abstract】 Objective To explore the efficacy and safety of consolidative TRT after first-line immunochemotherapy in ES-SCLC patients. Methods Thirty-five ESSCLC patients treated with first-line immunochemotherapy February 2024 to April 2025 were divided into cohort A(n=19, no TRT) and cohort B(n=16, with consolidative TRT). Primary endpoints: OS, PFS; secondary endpoint: treatment safety. Results Thirty-five ES-SCLC patients(cohort A: n=19; cohort B: n=16). Median PFS: 5.3 vs. 9.1 months(P<0.05); median OS: 6.3 vs. 10.3 months(P<0.05). No significant difference in treatment-related adverse reaction incidence(P>0.05). Conclusion TRT after immunochemotherapy improves PFS and OS and is safely controllable.更多还原